ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2023; 13(7):2257-2258. doi:10.7150/thno.84874 This issue Cite
Erratum
Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum
Hui-Min Lei1,2*, Ke-Ren Zhang1*, Cong Hui Wang1*, Yang Wang1, Guang-Lei Zhuang3, Li-Ming Lu4, Jian Zhang5, Ying Shen1,2 
, Hong-Zhuan Chen1,2 , Liang Zhu1,2
1. Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Shanghai Collaborative Innovation Center for Translational Medicine, Shanghai, 200025, China
3. State Key Laboratory of Oncogenes and Related Genes, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
4. Central laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China; Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
5. Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao-Tong University School of Medicine, Shanghai 200025, China.
* These authors contributed equally to this study.
Citation:
Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum. Theranostics 2023; 13(7):2257-2258. doi:10.7150/thno.84874. https://www.thno.org/v13p2257.htm
Other stylesCorrected-article in Theranostics, Volume 9, 7122
Four transwell sub-pictures in Figure 6 (6B, siSOD2 Mock treatment on EV group and Mock treatment on ALDH1A1 group; 6C, siGPX4 Mock treatment on EV group; and 6H, NAC+siALDH1#4 treatment on HCC827 cells) were inadvertently misplaced. The correct version is shown below. Additionally, we would like to modify the legend text for Supplementary Figure S1(G) to read, “Expression of the ALDH1A1 protein was confirmed by western blot analysis which was performed concurrently with the western analysis shown in Figure 2A”.
The corrigendum does not affect any result or conclusion of the paper. The authors sincerely apologize for any inconvenience this may have caused.
Figure 6
Corrected Figure 6 B, C, and H
Author contact
Corresponding authors: jyzhuledu.cn (L. Z.), yaoliedu.cn (H. Z. C), yshen0510edu.cn (Y. S.)
Published 2023-4-15
Citation styles
APA
Lei, H.M., Zhang, K.R., Wang, C.H., Wang, Y., Zhuang, G.L., Lu, L.M., Zhang, J., Shen, Y., Chen, H.Z., Zhu, L. (2023). Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum. Theranostics, 13(7), 2257-2258. https://doi.org/10.7150/thno.84874.
ACS
Lei, H.M.; Zhang, K.R.; Wang, C.H.; Wang, Y.; Zhuang, G.L.; Lu, L.M.; Zhang, J.; Shen, Y.; Chen, H.Z.; Zhu, L. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum. Theranostics 2023, 13 (7), 2257-2258. DOI: 10.7150/thno.84874.
NLM
Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum. Theranostics 2023; 13(7):2257-2258. doi:10.7150/thno.84874. https://www.thno.org/v13p2257.htm
CSE
Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L. 2023. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas: Erratum. Theranostics. 13(7):2257-2258.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.